Sepracor faces setbacks with two drugs
This article was originally published in Scrip
Sepracor has been hit with a double setback as its mid-stage antidepressant SEP-225289 failed a Phase II study, and two paediatric studies of its best-selling sedative Lunesta (eszopiclone) have been placed on hold.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.